PreAnalytiX GmbH, a joint venture between QIAGEN N.V. (NYSE: QGEN; Frankfurt, Prime Standard: QIA) and BD (Becton, Dickinson and Company; NYSE: BDX), today announced the launch of the PAXgene® Urine Liquid Biopsy Set, which enables the reliable analysis of cell-free DNA (cfDNA) from urine with most molecular testing technologies, including qPCR, digital PCR and next-generation sequencing (NGS). The new set will be commercialized by QIAGEN.

Astek Diagnostics and Key Technologies announced on Tuesday that they have partnered to develop a benchtop analyzer that will be used to diagnose urinary tract infections.

In a new study looking at the long-term effects of hospitalized patients who have acute kidney injury, Johns Hopkins Medicine researchers found that higher levels of certain biomarkers in urine and blood can predict a patient’s risk of developing chronic kidney disease.

Recently, Shenzhen Superbio Technology Co., Ltd. Fentanyl Drug Abuse Detection Kit (fluorescence chromatography method) has obtained 510 (k) pre-market notification, which is the world's first POCT product approved by the US FDA for the detection of fentanyl by fluorescence method.